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Abstract
Backgrounds: Cryptococcal meningitis (CM) has been known to lead to significant morbidity and mortality. The
relative contribution of the complement system in protection and pathogenesis during CM remains largely
unknown. The purpose of this study was to evaluate the baseline complement component profiles in human
cerebrospinal fluid (CSF) and plasma from non-HIV patients with CM, and therefore to provide insights of possible
roles of the complement system in CM.
Methods: CSF and blood samples from forty two CM patients not infected with HIV and thirteen non-CM control
patients (Ctrl) were retrospectively selected and evaluated from the patients admitted to the hospital with a suspected
diagnosis of CM. CSF and blood samples were collected at the admission. Enzyme-linked immunosorbent assay (ELISA)
for complement components, cytokine IL-12 and western blot for C3 activation were performed on CSF and plasma
samples. The levels of complement C1q, factor B (FB), mannose binding lectin (MBL), C2, C3, C4, C5, C4 binding protein
(C4BP), Factor I (FI), Factor H (FH), sC5b-9 in CSF and plasma samples were compared. Pearson’s correlation coefficients
were calculated on variables between complement components and the levels of total protein in the CSF samples.
Results: Our data demonstrated that the CSF levels of complement components of C1q, FB, MBL as well as
complement pathway factors sC5b-9 and complement regulator FH were all elevated in patients with CM as
compared to the controls, CSF C3 breakdown products iC3b were found in both CSF and plasma samples of the
CM patients. A positive correlation was found between the levels of CSF protein and MBL, C1q or FB.
Conclusions: The activity of the complement system in CSF was increased in non-HIV patients with CM. C1q,
MBL and FB are the important participants in the complement activation in CM. The relative contribution of each
of the specific complement pathways and complement cascades in protection and inflammation resolution
against CM warrant further investigation.
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Background
Cryptococcal meningitis (CM) is one of the most common
diseases in HIV patients and other immune-compromised
patients [1]. Over 1 million CM cases with 600,000 deaths
per year in HIV patients worldwide have been reported [2].
Additionally, non-HIV related CM also contributes a sig-
nificant mortality and morbidity in the developed world
despite advances in antifungal therapy [1]. In China, the
main pathogen of cryptococcal infections is C. neoformans,
resulting in pulmonary cryptococcosis that has a predilec-
tion to disseminate to the central nervous system (CNS)
leading to life threatening meningoencephalitis [3].
The complement system is well known as a major
component of the host innate immune defense system
against infection. Activation of the complement system
in response to invading pathogens is initiated through
the classical (CP), alternative (AP) and lectin (LP) path-
ways. Activation results in C3 cleavage, releasing ana-
phylatoxins C3a and C5a, and formation of a membrane
attack complex to lyse the target cells. Cleavage of C3
generates the key opsonins, C3b and iC3b. These pro-
teins tag the pathogens for phagocytosis [4]. The com-
plement system has the inhibitory proteins to regulate
the location and efficacy of complement activation. Key
fluid phase complement regulators include Factor H
(FH), Factor I (FI), C4-binding protein (C4BP) and C1
inhibitor (C1INH).
It has been suggested that the complement system is
of central importance in host defense against bacterial
meningitis. Mice deficient in C1q and C3 demonstrated
a decreased survival and enhanced growth of pneumo-
cocci in cerebrospinal fluid (CSF) after induction of men-
ingitis [5]. Complement factors C1q, MBL, C3a, iC3b,
C5a, sC5b-9 and FH were all elevated in CSF of patients
with bacterial meningitis as compared to the controls [6].
Depletion of C3 or elevated C5a levels in CSF of patients
with pneumococcal meningitis was associated with poor
clinical prognosis [7, 8].
In contrast to bacterial meningitis, most fungal micro-
organisms cause a chronic instead of an acute or sub-
acute meningitis [9]. Investigations from animal model
and human patients have shown the importance of the
complement system against cryptococcal infections [10].
Mice lacking hemolytic complement activity in their sera
were sensitive to C.neoformans [11]. Guinea pigs and mice
treated with cobra venom (depletion of C3 to C9) showed
reduced ability to clear C.neoformans from extraneural
sites [12]. C5−/− mice were more susceptible to intraven-
ously injected C.neoformans, and more easily developed
acute, fatal cryptococcal pneumonia [13]. Patients with
cryptococcal fungemia showed reduced levels of C3 and
FB [14]. Brain sections from patients with CM did not
show C3 binding to the pathogen [15]. Moreover, both
the classical and alternative complement pathways play
a critical role in opsonophagocytosis of C.neoformans
by neutrophils [16]. In vitro experiments demonstrated
that C5a-C5aR signaling guided neutrophils to migrate
to C.neoformans, resulting in optimal phagocytosis and
subsequent killing of the organisms [17]. The complement
opsonization is required in the anti-cryptococcal activity
of human dendritic cells and macrophages [18, 19]. These
data suggest that the major functions of the complement
system are to stimulate the chemotaxis of the phagocytic
effector cells and enhance the uptake of cryptococcal cells
by these phagocytes. Complement functionality can be
crucial to fight off and kill invading Cryptococcus.
To our knowledge, no study has been reported which
examines the complement system activity in CSF and
plasma from CM patients. The purpose of this study was
to investigate whether the complement system is activated
systemically and/or intrathecally during CM. The levels of
the complement components in CSF and plasma samples
from CM patients were determined and compared with
that in the patient control group who were diagnosed with
pulmonary cryptococcosis without CNS infection and in-
flammation involvement.
Methods
Patient selection, clinical sample collection and processing
This study was carried out from November 2014 to
December 2015 at Huashan Hospital, Shanghai China.
Both lumbar CSF and plasma samples were simultan-
eously obtained from patients with a suspected CM diag-
nosis at admission for routine chemistry, cytology and
culture analysis. Venous blood was collected from individ-
uals for plasma and routine blood cell and culture analysis.
The remaining CSF samples were centrifuged and single
use aliquots of these samples were stored at −80 °C.
CM group and patient control group were retrospect-
ively selected from the collected samples. CM group
consisted of 42 patients who were ≥18 year old and not
infected with HIV with a first episode of CM as diag-
nosed according to the criteria reported previously [20].
Confirmed cases were patients meeting the laboratory
criteria with positive culture of C. neoformans or positive
India ink smear of CSF. Possible cases were patient with
positive cryptococcal antigen titer in undiluted CSF and
met at least one of the following criteria : (1) abnormal
laboratory tests or an increased open pressure (≥200
mmH2O) of CSF, (2) abnormalities of cranial imaging
(Computerized Tomography or Magnetic Resonance
Imaging) which could not be explained by other factors.
Cryptococcal antigen in CSF was determined with the
Latex-Cryptococcus antigen detection system (Immuno-
Mycologics) [21].
Control CSF or blood samples were obtained from pa-
tients who presented to the hospital with suspicion of
CM but subsequently tested negative for CM or any
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other pathogen in CSF with normal CSF leukocyte count
and protein concentration. The control patients were diag-
nosed as pulmonary cryptococcosis based on histologic
presence of the organism in lung biopsy specimens, or
positive result of the serum cryptococcal antigen test with
radiographic characteristics of pulmonary disease. [22].
The ethical and scientific committee of the College of
Medicine, Fudan University approved this study.
ELISA
Human Complement C1q, FB, MBL, C2, C3, C4, C5,
C4BP, FH, FI, sC5b-9, and cytokine Interleukin (IL) -12
were measured with commercial ELISA kits (Cusabio
Biotech, Wuhan, P.R. China, R&D Systems, Minneapolis,
USA, Abcam, Cambridge, UK, QuidelSan Diego, USA).
Experiment protocols were followed according to the
manufacturer’s instructions.
Western blot
For comparison of complement C3 activation in CSF
and plasma samples, 20 μl of CSF and 2 μl of plasma
samples were loaded on an SDS-PAGE gel. Samples were
transferred to polyvinylidene difluoride (PVDF) mem-
branes. The membranes were blocked and then incubated
with mouse anti-human C3/C3b/iC3b/C3dg monoclonal
antibody (1:1,000, Cedarlane, Ontario, Canada) in TBST
(Tris-buffered saline supplemented with Tween 20) con-
taining 5% dry milk at 4 °C overnight. Blots were then
washed and incubated with goat anti-mouse IgG (1:15,000,
LI-COR Bioscience, Nebraska, USA) diluted in TBST con-
taining 2% dry milk. The membranes were developed with
an Odyssey system (Li-COR Bioscience) according to the
manufacturer’s protocol.
Statistical analysis
Results were graphed and analyzed using Prism 5.0
(GraphPad). Comparisons between the CM and control
groups were made using unpaired t tests or Mann–
Whitney tests (when the variances were significantly
different). Nominal data were analyzed with Fisher exact
test or Chi χ2 test. Pearson’s correlation coefficients were
calculated on the variability between the levels of CSF
complement components and CSF total protein. In all
cases, a p value of <0.05 was set as the measure of
significance.
Results
The clinical characteristics of participants
The study groups consisted of 42 CM patients and 13
patients diagnosed with pulmonary cryptococcosis without
CNS infection and inflammation served as Ctrl group. As
shown in Table 1, there were no significant differences
in gender, age, blood routine test, CSF concentration of
glucose and chloride between the two groups. However,
WBC counts and concentrations of protein in CSF
were significantly higher in CM group than that in the
Ctrl group.
Complement components in CSF and plasma samples
The CSF concentrations of C1q, MBL and FB of CSF in CM
were greatly elevated compared to that in Ctrl, and
correlated with CSF protein concentrations
We first examined the concentrations of the comple-
ment classical pathway component (C1q), the lectin
pathway (MBL) and the alternative pathway (FB) in
plasma and CSF samples from CM and Ctrl group. The
concentrations of C1q, MBL and FB in CSF samples
were significantly higher in CM group than that in Ctrl
group (Fig. 1a). The mean CSF concentration of C1q was
1673.14 ng/ml in the CM group, but only 162.72 ng/ml in
the Ctrl group. The mean concentration of MBL was
5.11 ng/ml in the CM group, but 0.38 ng/ml in the Ctrl
group. The mean concentration of FB was 5.73 ng/ml in
the CM group, but 1.88 ng/ml in the Ctrl group. More-
over, CSF concentrations of C1q, MBL and FB were found
to be correlated to CSF protein levels (r = 0.5804 for C1q,
p-value =0.0479, r = 0.7061 for MBL, p-value = 0.0003, and
r = 0.6716, p-value =0.009). However, There were no
Table 1 The clinical characteristics of participants
Ctrl CM p value
Gender, M/F 9/4 28/14 0.5740
Age (means ± SEM, years old) 46.38 ± 11.15 44.86 ± 14.14 0.7233
Blood WBC (means ± SEM, 106/mm3) 6.98 ± 2.67 8.20 ± 3.75 0.2981
CSF WBC (median, 103/mm3) 2 9 0.0022
CSF Protein (median, mg/l) 387.5 883 0.0006
Blood Sugar (median, mmol/l) 5.4 6.9 0.5631
CSF Glucose (median, mmol/l) 2.65 2.70 0.4762
CSF Chloride (median, mmol/l) 121 120 0.3703
CM: cryptococcal meningitis group
Ctrl: control group
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statistical significances of the plasma concentrations of
C1q, MBL and FB between the CM and Ctrl groups
(Fig. 1b), suggesting that increased concentrations of C1q,
FB and MBL in CSF is a localized phenomenon.
The concentrations of complement components C2, C3, C4
and C5 in plasma and CSF samples
We further examined the concentrations of C2, C3, C4
and C5 in the plasma and CSF samples. There were no
statistical significances of the concentrations of these
complement factors in both plasma and CSF samples
between the two groups (Fig. 2a and b).
C3 activation in CSF and plasma in CM
The complement system activation is mediated through
the CP, AP and LP pathways. Each pathway converges at
the C3 convertase level resulting in C3 cleavage. To fur-
ther assess whether the C3 activation is involved in CM,
levels of C3 breakdown products in CSF and those in
simultaneously collected blood plasma samples were
evaluated by Western blot. C3 cleavage fragments iC3b
was detected in CM group from both plasma and CSF
samples (Fig. 3).
The concentrations of sC5b-9 in plasma and CSF samples
To determine the complement terminal pathway activa-
tion, we examined the concentrations of sC5b-9 in plasma
and CSF samples in Ctrl and CM groups. There was no
significant difference in plasma concentrations of sC5b-9
between the two groups. However, the CSF concentrations
of sC5b-9 in CM group was significantly higher than that
in the Ctrl group (p = 0.0064) (Fig. 4).
The concentrations of C4BP, FI and FH in plasma and CSF
The complement system is regulated by some key fluid
regulators, such as C4BP, FI and FH. We next measured
the concentrations of these factors in plasma and CSF
samples. There were no significant differences in the
plasma concentrations of C4BP, FI and FH expressed be-
tween Ctrl and CM groups (Fig. 5a). The concentrations
of C4BP and FI in CSF were also similar in both Ctrl
and CM groups (Fig. 5b). However, the CSF concentra-
tions of FH increased significantly in CM group compared
to the Ctrl group (p = 0.0303) (Fig. 5b).
The levels of IL-12 in the plasma and in CSF samples
We next investigated the levels of IL-12 because it may
plays an important role in host defense in CM [23]. As
Fig. 1 The concentrations of C1q, MBL and FB in plasma and CSF samples. The white bar represented Ctrl group and the gray bar represented
CM group. a CSF concentrations of C1q, MBL and FB were significantly higher in the CM group than those in the Ctrl group. b There were no
significant differences in plasma concentrations of three complement components among the Ctrl and CM groups
Fig. 2 The concentrations of C2, C3, C4 and C5 were detected in both plasma (a) and CSF (b) samples. There were no significant differences
between the CM and Ctrl groups
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shown in Fig. 6, though the plasma levels of IL-12 were
similar between the Ctrl and CM groups, the CSF levels
of IL-12 were significantly higher in CM group than that
in Ctrl group (p = 0.0121) (Fig. 6).
Discussion
In this study, we showed elevated CSF concentrations of
C1q, MBL, FB, sC5b-9 and FH in CM patients compared
to that in the control group and the common comple-
ment pathway factors iC3b in both CSF and plasma sam-
ples of CM patients. Our data suggest that the increased
CSF complement system activity might indicate its im-
portant roles in host defense and pathogenesis in CM.
Though the importance of the complement system to
C. neoformans infection is well established, it is not clear
how the complement system responds to pathogens in
CM clinically. The brain may represent its own charac-
teristics not like other organ when infected with Crypto-
coccus. There are few publications in this field. Our data
demonstrated that complement components including
the initiators of three complement pathways (C1q, FB
and MBL), other complement factors (C2, C3, C4, C5)
and regulators (FH, FI, C4BP) were present in CSF in
CM. Moreover, CSF levels of C1q, MBL, and FB were
significantly higher compared with that in control group.
In this study, we showed C3 and the complement terminal
pathways were activated in CSF during CM. Cleavage of
C3 generates the key opsonins, C3b and iC3b for
phagocytosis [24]. Activation of the complement ter-
minal pathway results in releasing anaphylatoxins C5a,
and formation of a membrane attack complex to lyse
the target cells. Meanwhile, sC5b-9 as the final product
of complement activation was significantly higher in
CSF in CM group than that in the control group. Our
results were similar with the report from Mook-Kanamori
et.al [6], which demonstrated that CSF levels of C1q,
MBL, FH and sC5b-9 were significantly elevated during
pneumococcal and meningococcal meningitis. Thus our
data suggest an important role of the complement system
in host protection against CM as well. C1q, MBL and FB
each separately initiates the classical, lectin and alternative
pathway, and plays a key role in the innate immune
system. C1q also take part in the clearance of apoptotic
cells during inflammation resolution [25, 26]. Signifi-
cantly elevated CSF levels of C1q, MBL and FB in CM
patients may reflect all of the three pathway activations
are involved in CM.
The differences of complement components between
the CM and Ctrl groups were only detected in CSF sam-
ples, not in the plasma samples. This indicates that local
inflammatory responses impact significantly on activity
of the complement system in CSF. The brain as a well-
developed organ of CNS is shielded by the blood–brain-
barrier (BBB) with tight junction formations. BBB is a
structural and functional barrier formed by the micro-
vascular endothelium, astrocytes and pericytes. The com-
plement system has taken part in various developmental
and regenerative processes, and is integrated with multiple
biological systems and pathways in many researches [27].
We think that the elevated CSF complement factors of pa-
tients with CM have leaked from the plasma because the
CSF complement levels of C1q, MBL and FB were signifi-
cantly correlated with the total concentrations of CSF pro-
tein. It is well known that a non-specific increase in
permeability of the blood-CSF barrier during meningitis
results in a rise in CSF protein concentrations including
all the plasma proteins [28]. However, complement factors
can be synthesized locally in the CNS [29]. Astrocyte and
glial cell are the main sources of complement in CNS [30,
31]. Previous study using Reibergram method demon-
strates that C3 and C4 were synthesized locally during
bacterial meningitis. Further studies using Reibergram are
needed to determine whether intrathecal synthesis of
complement factors is, at least in part, responsible for the
increased levels of CSF complement factors in CM.
However, complement has been described as a double-
edged sword since activation of the complement system
Fig. 3 C3 cleavage fragments were analyzed by western blot.
Approximately 20 μl of CSF and 2 μl of plasma samples were subjected
to SDS-PAG. The immunoreactive bands corresponding to C3α and iC3b
are denoted. Prominent iC3b band was found in the CSF and plasma
samples in CM patients. A representative is shown
Fig. 4 The concentrations of sC5b-9 in plasma and CSF. The
concentration of sC5b-9 in CSF increased significantly in CM
group compared to the Ctrl group and the p value was 0.0064
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significantly contributes to the pathogenesis of various
acute and chronic inflammatory diseases [32]. Adequate
regulation of the complement system is a central com-
ponent of the system’s ability to control unintended
complement activation on host cells. The expression of
regulator also can be detected in CSF, such as C4BP, FI,
and FH. Their amounts are nearly the same in CSF and
plasma. However, CSF FH concentrations were obviously
higher in CM than that in the control group. FH regu-
lates the AP both in the fluid phase and on cell surfaces.
Expression of FH regulators indicates the balance also
exits to control the degree of activation of complement.
The role of the complement system activation in host
defense and neuro-inflammation in CM is not fully
understood. Elucidating which components of the com-
plement system are important in both protective and
inflammatory roles in CM to drive development of
CM-specific immunotherapies.
It is well known that a Th1-driven cell-mediated re-
sponse is necessary for the control of C. neoformans in-
fections. Beenhouwer and his colleagues found that the
relative inherent susceptibilities of the mouse strains to
C. neoformans were as follows: IL-12−/− > IL-6−/− >
C57BL/6 > > IL-10−/− [33]. In the present study, the
CSF concentrations of IL-12 were significantly higher
in CM group than that in Ctrl group. In mirror with
other reports, our data indicated a protective role of
IL-12 in CM. Exploring underlying mechanisms in
regulation of IL-12 production and the cross talk with
the complement system in CM would provide a new
perspective for treatment of CM.
Conclusion
In conclusion, our data revealed the presence of the com-
plement components and the complement activation in
CSF in non-HIV patients with CM, and suggested an
important role of complement factors C1q, MBL, FB, FH
and sC5b-9 in the pathogenesis of CM. Further studies
are warranted to confirm the pathophysiological role of
these complement factors in CM and to stimulate the
development of new therapeutic strategies for CM by
directing treatment to specific pathways within the com-
plement cascade.
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